Biotech’s Biggest Stories: Drug Pricing, Access & R&D
From billion-dollar drug development bets and looming patent cliffs to drug pricing, patient access and the future of U.S. clinical trials, some of the biggest stories in biotech are connected by one question: what will they mean for the medicines patients ultimately receive?
In this episode of the Making Medicine Podcast, host John Stanford breaks down the stories he’s reading and watching across biotechnology, pharmaceuticals and healthcare policy, and explains why they matter beyond the headlines.
We begin with the enormous financial risk behind pharmaceutical R&D, including the fallout…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.